Database : MEDLINE
Search on : carcinosarcoma [Words]
References found : 5951 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 596 go to page                         

  1 / 5951 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29400015
[Au] Autor:Matsuo K; Ross MS; Machida H; Blake EA; Roman LD
[Ad] Address:Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
[Ti] Title:Trends of uterine carcinosarcoma in the United States.
[So] Source:J Gynecol Oncol;29(2):e22, 2018 Mar.
[Is] ISSN:2005-0399
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare type of high-grade endometrial cancer (EC) that has been understudied with population-based statistics due to its rarity. This study examined temporal trends in the proportion of UCS among women with EC. METHODS: This is a retrospective observational study examining The Surveillance, Epidemiology, and End Results program between 1973-2013. Primary EC cases were eligible for analysis, and a time-specific proportion of UCS was examined during the study period. RESULTS: UCS was seen in 11,000 (4.7%) women among 235,849 primary EC cases. Mean age at UCS diagnosis increased from 65.9 to 71.7 years between 1973-1989 and then decreased from 71.7 to 67.0 years between 1989-2013 (both, p<0.001). Proportion of Black women significantly increased during the study period (11.9%-20.0%, p<0.001), whereas the proportion of White women decreased from 86.0% to 60.5% between 1987-2013 (p<0.001). There was a significant increase in the proportion of UCS among primary EC from 1.7% to 5.6% between 1973-2013 (p<0.001). Among type II ECs (n=76,118), the proportion of UCS also increased significantly from 6.0% to 17.5% between 1973-2013 (p<0.001). An increasing proportion of UCS was seen in both young and older women but the magnitude of interval increase was larger in the older age group between 1973-2013 (<60 years, from 1.3% to 3.3%. p<0.001; and ≥60 years, from 2.6% to 7.0%, p<0.001). CONCLUSION: Our study demonstrated that the proportion of UCS has significantly increased among EC, accounting for more than 5% in recent years.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.3802/jgo.2018.29.e22

  2 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29240878
[Au] Autor:Rahouma M; Kamel M; Narula N; Nasar A; Harrison S; Lee B; Stiles B; Altorki NK; Port JL
[Ad] Address:Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.
[Ti] Title:Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database.
[So] Source:Eur J Cardiothorac Surg;, 2017 Dec 11.
[Is] ISSN:1873-734X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:OBJECTIVES: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignant neoplasm that accounts for a small percentage of non-small-cell lung carcinoma (NSCLC). At least 10% of PSCs has a spindle and/or giant cell component, which is often associated with a poor prognosis. We reviewed the Surveillance, Epidemiology, and End Results (SEER) database for the clinicopathological characteristics and surgical outcomes of PSCs. METHODS: The SEER database (1973-2013) was queried for PSC. A comparison between PSC and other NSCLC patients was performed. Cox regression for overall survival (OS) and logistic regression for node-positive predictors were performed. A propensity-matched (1:2) analysis (including age, gender, grade and stage) among surgically treated cases was done to compare OS in PSC versus other NSCLCs. RESULTS: A total of 955 899 NSCLC patients were identified; of these, 4987 patients had been diagnosed with PSC (0.52%). Men represented 60.9% of cases, with a median age of 68 years. The median size of the tumour was 5 cm and 3.5 cm in PSCs and NSCLCs, respectively (P < 0.001). PSC patients had significantly less Stage I, more high-grade tumours, advanced T stage, N+ disease and M1 disease (P < 0.001). In the PSC cohort, the most significant predictor of N+ disease on multivariate analysis was advanced T stage (P < 0.001). Predictors of OS in Stages I/II PSC on multivariate analysis were advanced age [P < 0.001, hazard ratio (HR) = 1.03], male gender (P = 0.024, HR = 1.25), carcinosarcoma (P = 0.002, HR = 1.76), grade (P = 0.033, HR = 1.81), T stage (P = 0.003, HR = 1.75), N status (P = 0.001, HR = 1.90) and surgical resection (P < 0.001, HR = 0.58). Among matched surgically resected cohorts, a poorer prognosis for OS was evident in PSCs in early stages (I/II) than in other NSCLCs (P = 0.009). CONCLUSIONS: PSC patients present with more advanced stage and with worse survival outcomes than other NSCLC patients. While surgical resection conveys a survival advantage in PSC, this group represents a population at a high risk for relapse and should be evaluated for novel adjuvant therapies.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/ejcts/ezx417

  3 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27779297
[Au] Autor:Han KH; Kim MA; Park NH
[Ad] Address:Department of Obstetrics and Gynecology, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Republic of Korea.
[Ti] Title:Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma.
[So] Source:Histol Histopathol;32(7):717-724, 2017 Jul.
[Is] ISSN:1699-5848
[Cp] Country of publication:Spain
[La] Language:eng
[Ab] Abstract:Uterine carcinosarcoma is a rare, aggressive, and biphasic tumor. It comprises carcinomatous and sarcomatous components, and mitosis-associated factors are thought to discriminate these two lesions. Aurora kinases are mitotic enzymes that are highly expressed in uterine malignancies. To identify the clinical significance of aurora kinase expression, we performed immunohistochemistry on tissue microarrays using cores selected from areas with typical carcinomatous and sarcomatous characteristics. A total of 24 samples were included, from patients at Seoul National University Hospital diagnosed with uterine carcinosarcoma, and who undergone a staging operation between 1997 and 2012. Patients' clinical and pathological data were analyzed, and expression patterns of aurora kinases were investigated. Aurora kinases A and B were dominantly expressed in the cytoplasm, and phospho-aurora kinases A and B were expressed in the nuclei. Phospho-aurora kinase A and aurora kinase B showed significantly higher expression in the carcinomatous component (P=0.012 and 0.008). High expression of phospho-aurora kinase A was associated with lymphatic metastasis such as positive pelvic lymph node and omental involvement (P=0.012 and 0.037). Overexpression of aurora kinase B was related to vascular invasion (P=0.011). High expression of both phospho-aurora kinase A and aurora kinase B was a prognostic factor for progression-free survival in uterine carcinosarcoma (P=0.049). In conclusion, expression of aurora kinases is associated with bidirectional tumor dissemination into the lymphatic and hematogenous pathways. In addition, high expression of phospho-aurora kinase A and aurora kinase B is a predictor of progression-free survival. Therefore, inhibitors of aurora kinases might be a prospective therapeutic options for uterine carcinosarcoma.
[Mh] MeSH terms primary: Aurora Kinases/biosynthesis
Carcinosarcoma/enzymology
Carcinosarcoma/pathology
Uterine Neoplasms/enzymology
Uterine Neoplasms/pathology
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
Aurora Kinase A/metabolism
Aurora Kinase B/metabolism
Aurora Kinases/genetics
Biomarkers, Tumor
Disease-Free Survival
Female
Gene Expression Regulation, Enzymologic/genetics
Gene Expression Regulation, Neoplastic/genetics
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Menopause
Middle Aged
Neoplasm Metastasis/pathology
Neoplasm Staging
Predictive Value of Tests
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Biomarkers, Tumor); EC 2.7.11.1 (AURKA protein, human); EC 2.7.11.1 (AURKB protein, human); EC 2.7.11.1 (Aurora Kinase A); EC 2.7.11.1 (Aurora Kinase B); EC 2.7.11.1 (Aurora Kinases)
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:161026
[St] Status:MEDLINE
[do] DOI:10.14670/HH-11-834

  4 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29504519
[Au] Autor:Salemis NS
[Ti] Title:Metaplastic carcinoma of the breast with mesenchymal differentiation (carcinosarcoma). A unique presentation of an aggressive malignancy and literature review.
[So] Source:Breast Dis;, 2018 Feb 27.
[Is] ISSN:1558-1551
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Metaplastic carcinoma of the breast with mesenchymal differentiation (MCMD), previously known as carcinosarcoma, is a very rare and aggressive tumor that has been recently classified as a subtype of metaplastic breast carcinoma. It accounts for 0.08%-0.2% of all breast cancers, with only a few cases reported in the literature. Histologically, MCMD is characterized by a biphasic pattern of malignant epithelial and sarcomatous components without evidence of a transition zone between the two elements. We herein describe a unique case of metaplastic carcinoma of the breast with chondrosarcomatous differentiation in a postmenopausal woman who presented with a large, rapidly growing, ulcerated, bleeding mass and signs of impending sepsis. Metaplastic breast carcinomas (MBC) are rare and aggressive tumors. They are characterized by larger size, lower rates of axillary node involvement, higher rates of triple negativity and distal metastases, earlier local recurrence and poorer survival compared with classic invasive breast cancer. Because of the rarity of MBC, the optimal treatment has not been well defined. Surgery is the main curative treatment modality since MBC has shown a suboptimal response to standard chemotherapy. Patients with MBC may be appropriate candidates for novel targeted therapies.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:Publisher
[do] DOI:10.3233/BD-170313

  5 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29482629
[Au] Autor:Li J; Liang P; Zhang D; Liu J; Zhang H; Qu J; Gao J
[Ad] Address:Department of Radiology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, Henan, 450008, China.
[Ti] Title:Primary carcinosarcoma of the liver: imaging features and clinical findings in six cases and a review of the literature.
[So] Source:Cancer Imaging;18(1):7, 2018 Feb 27.
[Is] ISSN:1470-7330
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Carcinosarcoma of the liver is a very rare tumor composed of a mixture of carcinomatous and sarcomatous elements. Less than 25 adequately documented cases have been reported, with inadequate description of imaging features. In order to improve the awareness of this rare tumor, this study aimed to analyze the clinicopathologic and imaging features of six cases of hepatic carcinosarcoma (HCS) confirmed by surgical pathologic evaluation. METHODS: We retrospectively studied the clinicopathologic and imaging features of six cases of HCS (matching the World Health Organization definition) and discussed the differential diagnosis on the basis of imaging findings. The patients, including five men and one woman, were 38 to 69 years of age. Five patients underwent CT scans, one underwent MRI scans. RESULTS: While 3 patients were positive for hepatitis-B surface antigen, 2 had cirrhosis. The largest tumor diameter ranged from 5.0 to 21.0 cm. Satellite nodules, venous thrombi, and organ invasion (gastric wall, gallbladder, and right adrenal gland) were identified. Pathologically, the carcinomatous components corresponded to hepatocellular carcinoma in three cases, cholangiocellular carcinoma in one case, and adenocarcinoma in two cases. The sarcomatous components exhibited complex features, with undifferentiated spindle cells in five cases and a leiomyosarcoma in one. All tumors showed heterogeneous density/intensity with extensive cystic change and necrosis; spot calcification was observed in one case. Capsule was not identified. While four tumors showed heterogeneous hypervascular enhancement, two showed hypovascular enhancement. All patients underwent surgical resection. The follow-up period ranged from 2 to 18 months. Four patients died from recurrence and metastasis. CONCLUSIONS: The clinical and imaging features of HCS are heterogeneous. Due to the heterogenous nature and very low morbidity of HCS, combination of careful analysis of imaging findings and clinical features might be useful for a more accurate diagnosis of HCS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:In-Process
[do] DOI:10.1186/s40644-018-0141-0

  6 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29492923
[Au] Autor:Zhang N; Deng J
[Ad] Address:Department of Gastroenterology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Centre for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China. natilen@163.com.
[Ti] Title:[Research progress of the clinically uncommon gastric carcinoma].
[So] Source:Zhonghua Wei Chang Wai Ke Za Zhi;21(2):228-235, 2018 Feb 25.
[Is] ISSN:1671-0274
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:Gastric cancer is one of the most important diseases that endangers people's health. Beside gastric adenocarcinoma, gastric carcinoma also includes the following types: adenosquamous carcinoma, squamous carcinoma, gastric neuroendocrine tumor, gastric hepatoid adenocarcinoma, AFP-producing gastric cancer, EBV-associated gastric cancer, lymphoepithelioma-like carcinoma, undifferentiated-type gastric cancer, gastric carcinosarcoma and so on. The adenosquamous carcinoma, squamous carcinoma of stomach, gastric hepatoid adenocarcinoma, AFP-producing gastric cancer and gastric carcinosarcoma mainly occurred in old men, while the linitisplastica gastric cancer was common in young women. It refers to the gastric cancers that are clinically rare and have lower incidence, unique histological and pathological features, however, without obviously clinical manifestations. The clinically uncommon gastric cancers are easy to be misdiagnosed or missed, and further to miss the optimal opportunity for treatment due to the unclearly specific pathogenesis and disease progression. With the development of studies on the clinically uncommon gastric carcinoma, although people have a further knowledge of its pathologic features, methods of diagnosis and treatment, the diagnosis and treatment standards for the clinically uncommon gastric cancer has not yet been established and unified. The therapeutic principle of the clinically uncommon gastric cancers is also the radical surgery, radiotherapy and chemotherapy as the main comprehensive treatment supplemented by individualized treatment. With lucubrating the pathogenesis of them, specific diagnostic methods and treatment measures are new hope for improving the diagnosis and treatment of the clinically uncommon gastric cancers. So, the further researches on the clinically uncommon gastric cancers and exploring their etiology, pathogenesis, histological and pathological features have important significance to their diagnosis and treatment. This article makes a summary of the clinically uncommon gastric cancers with the aspects of epidemiology, histology, pathology, diagnosis, treatment, to provide reference to clinical diagnosis and scientific studies.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Process

  7 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29488261
[Au] Autor:Kamii M; Kuroda H; Suzuki K; Isonishi S
[Ad] Address:Department of Obstetrics and Gynaecology, Jikei Daisan Hospital, Komae-shi, Tokyo, Japan.
[Ti] Title:Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma.
[So] Source:Cytopathology;, 2018 Feb 28.
[Is] ISSN:1365-2303
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1803
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:Publisher
[do] DOI:10.1111/cyt.12527

  8 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29483412
[Au] Autor:Nishikawa T; Yonemori K; Hasegawa K; Fujiwara Y; Fujiwara K
[Ad] Address:Dept. of Gynecologic Oncology, Saitama Medical University International Medical Center.
[Ti] Title:[I. Clinical Development and Prospect of Chemotherapy for Uterine Carcinosarcoma].
[So] Source:Gan To Kagaku Ryoho;45(2):234-238, 2018 Feb.
[Is] ISSN:0385-0684
[Cp] Country of publication:Japan
[La] Language:jpn
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Data-Review

  9 / 5951 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29470881
[Au] Autor:Páramo AA; Valverde DP; Campos PV; Santos EPG; Puche JLB; Guerrero PN; Delgado M; Fernindez JM
[Ti] Title:Carcinosarcoma sincrónico de la vesícula y la via biliar extrahepática. [Syncrhonous carcinosarcoma of the extrahepatic bile duct and gallbladder.]
[So] Source:Acta Gastroenterol Latinoam;46(1):30-34, 2016 Mar.
[Is] ISSN:0300-9033
[Cp] Country of publication:Argentina
[La] Language:spa
[Ab] Abstract:Carcinosarcoma is a malignant neoplasm characterized for intermingled epithelial and mesenchymal components. CASE REPORT: A preoperative suspected diagnosis will allow a radical therapy avoiding a very bad prognosis. We report on a male patient who was operated in our Service with diagnosis of synchronous carcinosarcoma of gallbladder and extrahepatic bile duct and a review of the Medical Literature. DISCUSSION: A gallblader carcinosarcoma showing extension into common bile duct is very rare, a carcinosarcoma of the bile duct is exceptional, and a synchronous carcinosarcoma ofthe bile duct and gallbladder has not been reported previously.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process

  10 / 5951 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29303935
[Au] Autor:Marcus JZ; Klobocista M; Karabakhtsian RG; Prossnitz E; Goldberg GL; Huang GS
[Ti] Title:Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas.
[So] Source:Int J Gynecol Cancer;28(3):500-504, 2018 Mar.
[Is] ISSN:1525-1438
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor α (ERα), estrogen receptor ß (ERß), and G protein-coupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined. METHODS: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ERα, ERß, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record. RESULTS: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ERα; all AS + SO tumor samples showed minimal to no immunoreactivity for ERα. There was a significant decrease in ERα H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor ß immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples. CONCLUSIONS: Higher expression of ERα and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERß and GPER expression, although significant differences in ERß and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERß and GPER do not seem to play a significant role in AS in this study.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:In-Data-Review
[do] DOI:10.1097/IGC.0000000000001183


page 1 of 596 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information